Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trialPietro Di Santo, Trevor Simard, Stephanie Skanes et al.|Critical Care|2021Cited by 54
1365 An active site PTPN2/N1 small molecule inhibitor promotes anti-tumor efficacy by sensitizing tumor cells to inflammatory signals and enhancing immune cell activityKathleen A. McGuire, Philip R. Kym, Christina K. Baumgartner et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1